Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Blood. 2011 Aug 25;118(8):2313-21. doi: 10.1182/blood-2010-12-324574. Epub 2011 Jul 6.
Plasminogen activator inhibitor-1 (PAI-1) is increased in the lungs of patients with pulmonary fibrosis, and animal studies have shown that experimental manipulations of PAI-1 levels directly influence the extent of scarring that follows lung injury. PAI-1 has 2 known properties that could potentiate fibrosis, namely an antiprotease activity that inhibits the generation of plasmin, and a vitronectin-binding function that interferes with cell adhesion to this extracellular matrix protein. To determine the relative importance of each PAI-1 function in lung fibrogenesis, we administered mutant PAI-1 proteins that possessed either intact antiprotease or vitronectin-binding activity to bleomycin-injured mice genetically deficient in PAI-1. We found that the vitronectin-binding capacity of PAI-1 was the primary determinant required for its ability to exacerbate lung scarring induced by intratracheal bleomycin administration. The critical role of the vitronectin-binding function of PAI-1 in fibrosis was confirmed in the bleomycin model using mice genetically modified to express the mutant PAI-1 proteins. We conclude that the vitronectin-binding function of PAI-1 is necessary and sufficient in its ability to exacerbate fibrotic processes in the lung.
纤溶酶原激活物抑制剂-1(PAI-1)在肺纤维化患者的肺部增加,动物研究表明,PAI-1 水平的实验操作直接影响肺损伤后瘢痕形成的程度。PAI-1 具有 2 种已知的特性,可能增强纤维化,即抑制纤溶酶生成的抗蛋白酶活性,以及与细胞黏附到这种细胞外基质蛋白相互干扰的 vitronectin 结合功能。为了确定 PAI-1 功能在肺纤维化中的相对重要性,我们向缺乏 PAI-1 的基因缺陷型博来霉素损伤小鼠给予具有完整抗蛋白酶或 vitronectin 结合活性的突变 PAI-1 蛋白。我们发现,PAI-1 的 vitronectin 结合能力是其加剧经气管内博来霉素给药诱导的肺瘢痕形成能力的主要决定因素。在博来霉素模型中,使用基因修饰表达突变 PAI-1 蛋白的小鼠证实了 PAI-1 的 vitronectin 结合功能在纤维化中的关键作用。我们得出结论,PAI-1 的 vitronectin 结合功能在加剧肺纤维化过程中是必要和充分的。